共 50 条
- [44] CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients [J]. OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (04):
- [45] Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients A Randomized Clinical Trial [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (01): : 33 - 42
- [46] Cytomegalovirus Antiviral Resistance Among Kidney Transplant Recipients in a Phase 3 Trial of Letermovir vs Valganciclovir Prophylaxis [J]. JOURNAL OF INFECTIOUS DISEASES, 2024,
- [47] Letermovir Prophylaxis for Cytomegalovirus REPLY [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (10): : 965 - 965
- [50] Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies [J]. OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (01):